Navigation Links
Presentation of Data on Progen's Cancer Epigenetic Targets Platform
Date:5/30/2008

BRISBANE, Australia, May 30 /PRNewswire-FirstCall/ -- (ASX: PGL; Nasdaq: PGLA) New data on Progen's cancer epigenetic targets program will be presented tomorrow at the American Association for Cancer Research (AACR) Epigenetics Meeting in Boston by Progen's collaborators at the Johns Hopkins University.

The data to be presented demonstrates that compounds in Progen's existing preclinical cancer epigenetics program functionally inhibit the activity of LSD-1, an exciting new epigenetic cancer target which, if inhibited, may activate genes that protect against tumor development. These LSD-1 inhibitors are the first to demonstrate effective re-expression of aberrantly silenced genes by targeting this recently discovered cancer gene regulator.

Dr. Laurence Marton, Progen's Chief Scientific Officer, said, "We have discovered from in vitro testing that by inhibiting LSD-1 with this new class of compounds we can reactivate genes that normally suppress cancer and are deactivated in cancer-triggering processes. We are now extending these studies to animal cancer models to determine if we can inhibit the growth of tumors."

"This is a new frontier in cancer treatment and we are excited to be entering this novel therapeutic area", said Dr. Marton.

Progen already has preliminary preclinical efficacy data for many of its cancer epigenetics compounds, and is planning to move additional related compounds into further efficacy, safety and pharmacokinetic models within the coming months.

About the AACR Cancer Epigenetic Special Conference: The AACR special conference on cancer epigenetics assembles prominent investigators in the field to discuss recent advances in this rapidly moving area. It provides a unique forum to review the remarkable progress in this area over the past few years, and provides a glimpse of where the field is moving, with a strong emphasis on translational epigenetics research.

About Progen: Progen Pharmaceuticals
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
5. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
8. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
9. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
10. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...utomation and intelligent clinical applications ta... level , , CHICAGO, Ill., Nov. 26 /PRNewswi...ens.com/healthcare ) highlights the ACUSON S2000(...e world,s first multi-use, automated volume breast...y and Annual Meeting of the Radiological Society o...
(Date:11/25/2008)...against expanding statin use broadly in wake of AH...ov. 25 JUPITER, a clinical trial s...r risk of healthy patients with elevated CRP, shou..., according to a national poll directed at health ...n the online poll conducted by medical news site M...
(Date:11/25/2008)...l Trial to Assess Survival of Patients Receiving L...able Hepatocellular Carcinoma , , BELLEVUE,...ology, Inc. (LSO) today announced the completion o... Light Infusion Therapy(TM) (Litx(TM)) as a treatm...), also known as hepatoma or primary liver cancer....
(Date:11/24/2008)...swire-FirstCall/ -- Leaders of Schering-Plough Cor...or investors on the company,s research pipeline, h...ncludes 46 new entities in clinical trials or unde... , , "Research and development is adding st...ue our transformation," said Fred Hassan, chairman...
Breaking Medicine Technology:Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 1ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 2ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 3ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 4American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 6090 1American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 6090 2Researchers identify how to switch off cancer cell genes 1186 1Earth Observation essential for geohazard mitigation 1184 1Earth Observation essential for geohazard mitigation 1184 2Earth Observation essential for geohazard mitigation 1184 3
...n,s pipeline provide support for,epigenetic and co...,data on use of Thalidomide to treat multiple myel...tCall/ -- Pharmion,Corporation reported today that...he company,s marketed and pipeline products will b...f Clinical,Oncology,s (ASCO) 43rd Annual Meeting i...
...2007 - Introgen Therapeutics, Inc.,(NASDAQ:INGN) r...N,241, the Company,s novel investigational mda-7/I...nced solid tumors., The data (Abstract #380), whic...e American Society of Gene Therapy, showed that,in...n all treated,tumors, including in those patients ...
Other Medicine Technology:Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 2Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 3Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 4Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 5Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 6Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 7Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3
(Date:12/1/2008)...news event -- Hall of States, Room 333 -- 444 Nort..., WASHINGTON, Dec. 1 ...oming together to outline the current fiscal situa...ext Administration to provide a recovery package t...rojects and ease the burden of Medicaid costs. As ...
(Date:12/1/2008)...wire/ -- An independent study at the,University o...want to play,video games at the same time as exer... , Fifty children aged 11 and 12 were asked...mes provided by a company called Gamercize. , ...they maintained movement on,the fitness machines....
(Date:12/1/2008)...Newswire/ -- Transcept Pharmaceuticals,Inc., a p...nounced today that,Glenn A. Oclassen, President &...ticipate at the RBC Capital Markets 2008 Healthcar... "Delivering Novel Drug Solutions: The Future of D... take place on Thursday, December,11, 2008 at 1:3...
(Date:12/1/2008)... Cardinal,Health and SR...ar supply and,co-marketing agreement to offer sur...oducts from Cardinal Health and reusable health ca...ment makes Cardinal Health the exclusive manufactu...400 disposable surgical kits. In,addition, the ag...
Breaking Medicine News(10 mins):Health News:Governors, Legislators Update Current State Fiscal Conditions, Push for Economic Recovery Package from Congress, President-elect 2Health News:Children Tell Researchers: We'll Get Fit if It's Fun 2Health News:Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel 2Health News:Cardinal Health, SRI Surgical Sign Five-Year Agreement For Surgical Kits 2Health News:Cardinal Health, SRI Surgical Sign Five-Year Agreement For Surgical Kits 3
...hKline (GSK) has reached an agreement with Eliot S... that it deceptively tried to delay competitors fr...-depressant drug Paxil.// GSK was allegedly inv... generic producers of Paxil in a bind of using fri...
...abani and his assistant Kartar Singh have been sen...of a fetus and then agreeing to abort it if it was... practitioner has been jailed for carrying out ill...ions. The perpetrators were found out when govern...
...onfections, Inc. of Dallas, Texas are tough nuts t...batch of production of Sam's Choice Belgian Milk C... almonds. This is a precautionary measure to ensur...ic to almonds that may cause a life threatening re...
... testing for HIV/AIDS in countries with high infec...er US president. // There was a stigma attached ...r those infected few decades ago and so AIDS testi... to Clinton, countries where there was no discrimi...
Other Medicine News:
The challenge for Carl Zeiss was to find innovative solutions for measurements on the eye and for preoperative computation of intraocular lenses (IOL). The result of this development work is the IOLM
Ahmed Glaucoma Valve (small size) with Pars Plana Clip .
Ahmed Glaucoma Valve.
...ompatibility is established. Provides a robust and...nsure correct positioning on the globe. Pressure R...h, when covered by Tenons tissue, acts as a Pressu...ive hypotony. The range of implants allows the sur...
Medicine Products: